325 related articles for article (PubMed ID: 23378569)
1. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Helin TA; Pakkanen A; Lassila R; Joutsi-Korhonen L
Clin Chem; 2013 May; 59(5):807-14. PubMed ID: 23378569
[TBL] [Abstract][Full Text] [Related]
2. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
[TBL] [Abstract][Full Text] [Related]
4. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
5. Warfarin replacements: good for patients, challenging for laboratories.
Eby CS
Clin Chem; 2013 May; 59(5):732-4. PubMed ID: 23487173
[No Abstract] [Full Text] [Related]
6. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
7. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
Samama MM; Guinet C; Le Flem L; Ninin E; Debue JM
J Thromb Thrombolysis; 2013 Feb; 35(2):140-6. PubMed ID: 23335022
[TBL] [Abstract][Full Text] [Related]
8. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
[TBL] [Abstract][Full Text] [Related]
9. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
10. Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Dias JD; Norem K; Doorneweerd DD; Thurer RL; Popovsky MA; Omert LA
Arch Pathol Lab Med; 2015 May; 139(5):665-73. PubMed ID: 25927150
[TBL] [Abstract][Full Text] [Related]
11. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
12. The new oral anticoagulants and the future of haemostasis laboratory testing.
Favaloro EJ; Lippi G
Biochem Med (Zagreb); 2012; 22(3):329-41. PubMed ID: 23092064
[TBL] [Abstract][Full Text] [Related]
13. Assays for measuring rivaroxaban: their suitability and limitations.
Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE
Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464
[TBL] [Abstract][Full Text] [Related]
14. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
15. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
Baglin T; Keeling D; Kitchen S;
Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737
[No Abstract] [Full Text] [Related]
16. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
Hillarp A; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Lindahl TL
J Thromb Haemost; 2011 Jan; 9(1):133-9. PubMed ID: 20946166
[TBL] [Abstract][Full Text] [Related]
17. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
18. The laboratory and the new oral anticoagulants.
Tripodi A
Clin Chem; 2013 Feb; 59(2):353-62. PubMed ID: 23043068
[TBL] [Abstract][Full Text] [Related]
19. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
20. Perioperative management of patients on new oral anticoagulants.
Lai A; Davidson N; Galloway SW; Thachil J
Br J Surg; 2014 Jun; 101(7):742-9. PubMed ID: 24777590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
